The SIRFLOX study evaluated the efficacy and safety of adding SIR-Spheres® Y-90 resin microspheres to a current first-line systemic chemotherapy in patients with non-resectable colorectal liver metastases.

SIRFLOX is the first large, randomized, controlled, open-label, multicenter international study to examine the use of chemo-radiotherapy in the first-line treatment of colorectal liver metastases.

With 530 patients recruited, SIRFLOX is the largest randomized interventional radiology study ever conducted in oncology.

SIRFLOX Study Design

SIRFLOX evaluated the patient benefits of adding SIR-Spheres Y-90 resin microspheres to a current first-line systemic chemotherapy regimen comprising mFOLFOX6 (with or without bevacizumab).

SIRFLOX recruited chemotherapy-naïve patients with non-resectable liver metastases from primary colorectal cancer, with or without limited extra-hepatic disease.

SIRFLOX design

The design of the SIRFLOX study has been published in BMC Cancer by Gibbs et al.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.